Considering the association of NAFLD/NASH with obesity and type 2 diabetes mellitus (T2DM), these pleiotropic effects make GLP-1 an attractive therapeutic target in patients with NAFLD/NASH. This evidence concerns the gene GCG and metabolic dysfunction-associated steatohepatitis.